<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BEPRIDIL HYDROCHLORIDE</span><br/>(be-pri'dil)<br/><span class="topboxtradename">Vascor<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">calcium channel blocker</span><br/><b>Prototype: </b>Verapamil<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 300 mg, 400 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Selectively blocks calcium ion influx across the cell membrane of cardiac muscle and vascular smooth muscle without changing
         serum calcium concentrations. Unlike other calcium channel blockers, it also blocks the sodium channel and possibly the potassium
         channel, resulting in quinidine-like effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bepridil reduces myocardial oxygen use and supply, and relaxes and prevents coronary artery spasm.</p>
<h1><a name="uses">Uses</a></h1>
<p>Chronic stable angina.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to bepridil HCl or any other calcium channel blocker, sick sinus syndrome or second or third-degree block,
         ventricular arrhythmias, hypotension, uncompensated cardiac insufficiency, congenital QT interval prolongation, and with concomitant
         use of drugs that prolong QT interval; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults; CHF, recent MI (<img src="../images/special/lesserorequal.gif"/>3 mo); serious hepatic or renal dysfunction;
         pregnancy (category C).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 200 mg once daily, may be adjusted every 7 d (max: 400 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food if nausea occurs.</li>
<li>Store away from light and moisture in tightly closed containers at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Nervousness, <span class="speceff-common">dizziness,</span> asthenia, <span class="speceff-common">headache.</span>
<span class="typehead">CV:</span> Negative inotropic effect, <span class="speceff-life">proarrhythmic effects (ventricular tachycardia or fibrillation, torsades de pointes</span>), CHF. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea,</span> dyspepsia. <span class="typehead">Hematologic:</span> Leukopenia, neutropenia, <span class="speceff-life">agranulocytosis</span> (all rare). <span class="typehead">Other:</span>
<span class="speceff-life">Death</span> has been reported in arrhythmia trials. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Adenosine</b> and <span class="classification">beta blockers</span> may increase risk of bradycardia. <b>Amiodarone</b> may lead to heart block; may increase <b>digoxin</b> levels and <b>digoxin</b> toxicity. May cause significant hypotension with <b>fentanyl.</b> Use with <span class="classification">diuretics</span> may increase risk of arrhythmias. <span class="classification">tricyclic antidepressants</span> may exaggerate prolongation of QT interval associated with bepridil. May enhance neuromuscular blockade induced by nondepolarizing
      agents such as <b>succinylcholine</b> and <b>tubocurarine;</b>
<b>warfarin</b> may increase free bepridil levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed from GI tract; approximately 60% reaches systemic circulation. <span class="typehead">Onset:</span> 60 min. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver, presumably by hepatic oxidative processes; 17 metabolites have been isolated. <span class="typehead">Elimination:</span> Approximately 65% excreted in urine in 10 d, 23% excreted in feces. <span class="typehead">Half-Life:</span> 42 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiac status, as bepridil can induce new arrhythmias, including ventricular tachycardia and fibrillation, and CHF</li>
<li>Monitor closely: Females over age 60 with hypokalemia and sinus bradycardia are at high risk for drug-induced torsades de
            pointes (a type of ventricular tachycardia).
         </li>
<li>Assess safety and need for help with ambulation or other activities (dizziness is a common adverse effect of this drug).</li>
<li>Monitor common adverse gastrointestinal effects (nausea, vomiting, diarrhea); determine need for intervention.</li>
<li>Lab tests: Monitor periodically serum transaminase levels, serum electrolytes, WBC with differential, digoxin level when used
            concurrently.
         </li>
<li>Report hypokalemia immediately. The condition should be promptly corrected.</li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report ringing in ears to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>